GLP-1 drugs

From seven combination hypotheses to one testable interaction: a gated agentic AI QSP workflow applied to healthy ageing interventions

bioRxiv · 1 Oct · Goryanin I, Goryanin I, Damms B

Mitochondrial Dysfunction in Type 2 Diabetes and Metabolic Syndrome: Mechanisms, Biomarkers, and Emerging Therapies

Diabetes, metabolic syndrome and obesity : targets and therapy · 23 Sept · Alghzawi HM, Younas S, Sahu S et al.

The Interplay of Metabolic Dysfunction, Neuroinflammation, and Mitochondrial Dysfunction in Balance Impairment: Insights from Type 2 Diabetes Mellitus and Alzheimer's Disease

Molecular neurobiology · 25 Sept · Fakorede S, Lateef OM, Udefa AL et al.

GLP-1 receptor agonists and podocyte senescence in diabetic kidney disease: structural pharmacology, mechanistic evidence, and multi-receptor agonism

Biochemical pharmacology · 23 Sept · Yue H, Wang Y, Guo X et al.

Rise or fall? Reconciling contested directions in human gut hormone aging

Gut hormones govern appetite and postprandial glucose handling, and both functions deteriorate with age - yet the human literature cannot agree on the direction of the underlying hormonal changes.

Frontiers in endocrinology · 7 Sept · Mavrych V, Shypilova I, Bolgova O

Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials

Research Square · 22 Sept · Dermit M, Colhoun HM, Goeminne LJE et al.

Convergent Astrocytic Failure in Parkinson's Disease: A System-Level Model of Pathogenesis and Treatment

A paradigm shift from a purely neurodegenerative disorder to a multicellular failure of the neuroglial unit has fundamentally redefined Parkinson's disease (PD).

Molecular neurobiology · 22 Sept · Abdelaziz AM, Fawzy MN, Shokr MM

Chronic low-grade inflammation drives skeletal aging and neurocognitive decline: inflammaging as a central hub coupling bone-brain aging

Global population aging has driven a marked rise in the co-prevalence of osteoporosis and cognitive impairment, and a bidirectional epidemiological association between the two conditions is now supported by multiple meta-analyses.

Frontiers in immunology · 4 Sept · Yu M, Wu Y, Wang A et al.

Aesthetic Considerations for Preventing and Managing GLP-1 Receptor Agonist-Related Facial Aging

The Journal of clinical and aesthetic dermatology · 1 Jul · Bommareddy K, Fabi S, Muniz M

Precise resistance training alleviates osteosarcopenia via the GLP-1/myostatin path: a 32-week randomized controlled trial and molecular mechanism study

Archives of physiology and biochemistry · 17 Sept · Sun L, Zhao P, Fan X et al.

Geroprotective Effects of Drugs Modulating Metabolic Pathways: Perspectives of Pharmacology in Anti-Aging Therapy

Aging is the strongest risk factor for chronic diseases such as cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders. Advances in geroscience indicate that pharmacological modulation of conserved molecular pathways may extend healthspan and delay multimorbidity.

International journal of molecular sciences · 22 Aug · Grycan M, Zyśk R, Grycan G et al.

GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension

Experimental gerontology · 14 Sept · Al-Ali D, El Hajj N

GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide)/GLP-1 Receptor Agonists for Antipsychotic-Induced Weight Gain: A Narrative Review

The clinical management of severe mental illness faces a profound longevity crisis, as second-generation antipsychotics, particularly clozapine and olanzapine, trigger severe weight gain and cardiometabolic complications that reduce life expectancy by 10 to 20 years.

Cureus · 12 Aug · Buczkowska A, Glinski M, Danieluk J et al.

Interactions between dietary intake and GLP-1 biology: implications for metabolic dysfunction and aging

Critical reviews in food science and nutrition · 7 Sept · Han Y, Shon J, Park YJ

Use of fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Asians with type 2 diabetes

Primary care diabetes · 4 Sept · Kong AP, O CK, Lai S et al.

Recent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 4 Sept · Lee CM, Kim JY, Shim JH et al.

A minimal three-arm oral regimen for healthspan: mechanistic alignment with transcriptomic signals from a large parental-lifespan GWAS

A large genome-wide association study of parental lifespan was reported in 2019.

Frontiers in aging · 19 Aug · Cheung N

Late-life semaglutide treatment slows ageing and extends lifespan in female mice

Pharmacological glucagon-like peptide-1 receptor (GLP-1R) activation reduces food intake and is an effective therapy for type 2 diabetes and obesity 1 . The use of GLP-1 medicines has revealed pleiotropic beneficial effects beyond glucose and weight control 2-5 , but little is known about the underlying basis of the pleiotropic effects.

Nature · 2 Sept · Feng Y, Barthez M, Wang Y et al.

Microbiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the Lifespan

Obesity arises from intertwined and reciprocal diet-microbiome-host pathways that reshape energy balance, insulin sensitivity, and inflammation.

Obesity reviews : an official journal of the International Association for the Study of Obesity · 2 Sept · Kalafati IP, Krongauz D, Bosco A et al.

Metabolic sarcopenia in the era of incretin-based therapy: a narrative review of mitochondrial determinants of muscle quality and emerging therapeutic strategies

Journal of Yeungnam medical science · 2 Sept · Park CH, Jeon JH, Kim MJ

The Neural Impact Score benchmarks drugs in Multi-Region Brain Organoids

bioRxiv · 27 Aug · Pantula A, Singh V, Sadul O et al.

Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity

Incretin-based therapies (IBTs), including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (GIP/GLP-1 RAs), have transformed the management of obesity and type 2 diabetes mellitus (T2DM).

Nutrients · 14 Aug · Mollero ELM, Dozzani I, Biamonte E et al.

Mechanisms of Hypertension in Women: Interactions Between Vascular Ageing, Metabolic Dysfunction, and Hormonal Regulation

Purpose: Hypertension in women is a dynamic, hormone sensitive condition shaped by cumulative physiological changes across the life course. This review summarises current evidence relating vascular ageing, hormonal regulation, metabolic dysfunction, and reproductive history to blood pressure regulation in women.

Biomedicines · 24 Jul · Hooshmandi S, Freestone NS, Arrigoni FIF

Mechanisms of Obesity-Related Kidney Disease: From Adipose Depot Biology to the Chymase-Aldosterone and Ghrelin-Leptin Axes

Obesity is an increasingly important and modifiable driver of chronic kidney disease (CKD), with effects that extend well beyond its associations with type 2 diabetes, hypertension, and dyslipidemia.

Biomolecules · 8 Aug · Hsu HC, Shih LJ, Hou YC et al.

Immunometabolic reprogramming via GLP-1 receptor agonists in people with HIV: A multidimensional systemic framework

Bioscience trends · 21 Aug · Sun L, Isnard S, Zhu H et al.

Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice

Chronic kidney disease is a major health burden. Given the therapeutic potential of GLP-1 receptor agonists (semaglutide, tirzepatide, and retatrutide) in diabetic nephropathy, we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO and aging models.

iScience · 13 Aug · Ding M, Li X, Wei Y et al.

Citrus Changshan Huyou extracts as natural GLP-1R agonists attenuate atherosclerosis via the GLP-1R/PKA/CREB pathway: a functional food perspective

Atherosclerosis (AS)-triggered cardiovascular diseases constitute a major global public health crisis. The pathological progression of AS is characterized by abnormal lipid accumulation, inflammatory cell infiltration and atherosclerotic plaque buildup in arterial walls.

Frontiers in nutrition · 5 Aug · Fang YY, Bao CY, Liu WZ et al.

The GLP-1-Mitochondria Axis in Metabolic Aging

Metabolic aging underlies a cluster of chronic conditions-type 2 diabetes, cardiovascular disease, sarcopenia, and neurodegeneration-that account for a substantial share of global morbidity and mortality.

Aging cell · 1 Aug · Chang R, Tsai AP, Wang B et al.

Chronic Disease and Disability in the United States: Trends, Inequities, and Imperatives for Policy Reform

Policy Points Position Universal, High-Quality Education as a Foundational Public Health Strategy. Long-term health and life expectancy in the United States are shaped more by educational attainment than by any other single factor.

The Milbank quarterly · 14 Aug · Mokdad AH, Dwyer-Lindgren L, Murray CJL

Lactiplantibacillus plantarum AS21 Attenuates Sex-Biased Glucose Intolerance in Aging Mice via Gut Mucosal Microbiota-Derived Citrulline

Aging-related metabolic decline, particularly impaired glucose tolerance, represents a growing challenge in aging populations. Probiotics are promising modulators of host metabolism; however, how sex differences influence their efficacy in mitigating metabolic aging remains poorly understood.

Aging cell · 1 Aug · Jia M, Chen M, Chen H et al.

Anti-Obesity Medications in Longevity and Aesthetic Medicine

Anti-obesity medications (AOMs), led by the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) semaglutide and liraglutide and the dual GIP/GLP-1 receptor agonist tirzepatide, have produced substantial weight reduction and growing signals of benefit that extend well beyond adiposity.

Journal of clinical medicine · 3 Aug · Bijoch J

National Cancer Institute-Supported Obesity and Cancer Research, 2015-2022

JAMA network open · 3 Aug · Dwyer LA, Agurs-Collins T, Bailey CP et al.

GLP-1 receptor agonists, metabolic syndrome, and Alzheimer's disease: Lessons and opportunities from the EVOKE trials

Metabolic syndrome and Alzheimer's disease (AD) are increasingly recognised as interconnected, sharing vascular, metabolic and inflammatory pathways that accelerate brain ageing and cognitive decline.

Journal of neuroendocrinology · 1 Aug · Gupta P, Pozzilli V, De Giovanni A et al.

A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health

Aging is a systems-level process linking metabolic dysfunction, inflammation, impaired repair, frailty, and multimorbidity, whereas existing pharmacological strategies usually optimize disease-specific endpoints such as weight loss or HbA1c rather than aging-related trajectories.

CPT: pharmacometrics & systems pharmacology · 1 Aug · Goryanin I, Damms B, Goryanin I

The Immunometabolic Bridge: Targeting Metainflammation to Prevent the Transition from Obesity to Cardiovascular Disease

Journal of inflammation research · 5 Aug · Wu M, Han Y, Liu L

Time-restricted eating promotes sustained fat loss in Drosophila

bioRxiv · 10 Aug · Gatto JA, Chang TY, Kanmogne WC et al.

Methionine tuning for health without frailty

Cell metabolism · 1 Aug · Garrido A, Price NL, de Cabo R